Ocuphire Pharma
preferred practice pattern reveals high unmet need in mild moderate and severe patients normal or minimal no no no no no sometimes rarely an oral option treatment options across all stages no no usually | Ocuphire Pharma
Company
Deck Type
Deck date
October 2022
Slide
23 of 53
Related slides by other companies
Matinas BioPharma
Investor Presentation
February 2024
high unmet medical need in treatment of invasive aspergillosis | Matinas BioPharma
Matinas BioPharma
Investor Presentation
January 2024
high unmet medical need in treatment of invasive aspergillosis | Matinas BioPharma
Oculis
Investor Presentation
April 2024
high unmet need for novel treatments for efficacy onset tolerability | Oculis
AN2 Therapeutics
IPO
March 2022
pipeline targets high unmet needs in rare chronic and serious infectious diseases lung disease boron chemistry approach enables targeting of novel biological targets mid phase topline data japan attest as an therapeutics | AN2 Therapeutics
Other recent decks by Ocuphire Pharma
See all presentations (10 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
May 2023
Results
January 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights